Scheinfeld Noah
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA.
J Drugs Dermatol. 2006 Mar;5(3):228-31.
Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending on the series reported. Maculopapular eruptions, erythematous eruptions, edema, and periorbital edema are the most common adverse events observed. Imatinib can also induce severe skin eruptions and generalized skin eruptions. Toxic epidermal necrolysis and Stevens Johnson syndrome has been linked to the use of imatinib. Imatinib has caused acute generalized exanthematous pustulosis. Purpuric vasculitis and mycosis fungoides-like reactions has occurred after imatinib use. Rarer side effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, pityriasis rosea, psoriasis, reactivation or induction of porphyria cutanea tarda, neutrophilic eccrine hidradenitis, Sweet's syndrome, erythema nodosum, EBV-positive cutaneous B-cell lymphoproliferative disease, possible induction of squamous cell, hyaline cell syringomas, follicular mucinosis, pseudolymphoma-type drug eruptions, and malpighian epitheliomas. Most cutaneous eruptions caused by imatinib do not necessitate discontinuance of imatinib and are usually self limited, despite continued treatment. Administration of oral or topical corticosteroids can ameliorate some of imatinib's cutaneous side effects.
伊马替尼引起的皮肤反应很常见，根据所报告的系列研究，发生率在9.5%至69%的患者中。斑丘疹、红斑疹、水肿和眶周水肿是观察到的最常见不良事件。伊马替尼还可诱发严重的皮肤疹和全身性皮疹。中毒性表皮坏死松解症和史蒂文斯-约翰逊综合征与伊马替尼的使用有关。伊马替尼曾引发急性全身性发疹性脓疱病。使用伊马替尼后发生了紫癜性血管炎和蕈样肉芽肿样反应。较罕见的副作用包括：色素减退、苔藓样反应、糠疹样皮疹、玫瑰糠疹、银屑病、迟发性皮肤卟啉病的再激活或诱发、嗜中性汗腺炎、Sweet综合征、结节性红斑、EBV阳性皮肤B细胞淋巴增殖性疾病、可能诱发鳞状细胞、透明细胞汗管瘤、毛囊黏蛋白病、假淋巴瘤型药疹和马尔皮基上皮瘤。伊马替尼引起的大多数皮肤疹并不一定需要停用伊马替尼，并且通常是自限性的，尽管继续治疗。口服或外用皮质类固醇的给药可改善伊马替尼的一些皮肤副作用。
